Denali Therapeutics (BSP:D2NL34) E10: R$-1.76 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:D2NL34 Denali Therapeutics Inc BSP:D2NL34
6 GF Score
Price R$27.06
! 6 Warning Signs
View Full Analysis

What is Denali Therapeutics E10?

Denali Therapeutics BSP:D2NL34 6 E10 is R$-1.76 as of Jun. 2026. GuruFocus rates BSP:D2NL34 with a GF Score™ of 6/100. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Denali Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was R$-3.484. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is R$-1.76 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-20), Denali Therapeutics's current stock price is R$27.06. Denali Therapeutics's E10 for the quarter that ended in Jun. 2026 was R$-1.76. Denali Therapeutics's Shiller PE Ratio of today is .


Denali Therapeutics  (BSP:D2NL34) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Denali Therapeutics E10 Related Terms


Denali Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Denali Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Denali Therapeutics E10 Chart

Denali Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Denali Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.76

BSP:D2NL34 vs RCUS, ALMS, ELVN: E10 Comparison

For the Biotechnology subindustry, Denali Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Denali Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Denali Therapeutics's Shiller PE Ratio falls into.


BSP:D2NL34
6GF Score
Denali Therapeutics Inc BSP:D2NL34
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Denali Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Denali Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-3.484/333.9520*333.9520
=-3.484

Current CPI (Jun. 2026) = 333.9520.

Denali Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201512 0.000 236.525 0.000
201612 -0.951 241.432 -1.315
201703 -7.381 243.801 -10.110
201706 -1.069 244.955 -1.457
201709 -0.830 246.819 -1.123
201712 -2.438 246.524 -3.303
201803 -0.853 249.554 -1.141
201806 -2.225 251.989 -2.949
201809 -1.561 252.439 -2.065
201812 3.068 251.233 4.078
201903 -1.575 254.202 -2.069
201906 -2.352 256.143 -3.066
201909 -1.977 256.759 -2.571
201912 -2.299 256.974 -2.988
202003 -2.687 258.115 -3.476
202006 -2.906 257.797 -3.764
202009 -2.916 260.280 -3.741
202012 9.826 260.474 12.598
202103 -3.268 264.877 -4.120
202106 -2.514 271.696 -3.090
202109 -3.643 274.310 -4.435
202112 -3.506 278.802 -4.200
202203 -2.637 287.504 -3.063
202206 -2.423 296.311 -2.731
202209 -4.405 296.808 -4.956
202212 -3.934 296.797 -4.426
202303 -4.167 301.836 -4.610
202306 6.310 305.109 6.907
202309 -3.556 307.789 -3.858
202312 -4.214 306.746 -4.588
202403 -3.386 312.332 -3.620
202406 -3.178 314.175 -3.378
202409 -3.489 315.301 -3.695
202412 -4.088 315.605 -4.326
202503 -4.491 319.799 -4.690
202506 -3.993 322.561 -4.134
202509 -3.969 324.800 -4.081
202512 -3.983 324.054 -4.105
202603 -3.608 330.213 -3.649
202606 -3.484 333.952 -3.484

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of R$-1.76 mean?
Denali Therapeutics (BSP:D2NL34) has a E10 of R$-1.76 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Denali Therapeutics and its competitors.
Is Denali Therapeutics' E10 too high?
Denali Therapeutics' current E10 is R$-1.76. Overall, Denali Therapeutics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' E10 compare to RCUS and ALMS?
Denali Therapeutics' E10 of R$-1.76 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Denali Therapeutics and its competitors. Denali Therapeutics's current E10 is R$-1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Denali Therapeutics (BSP:D2NL34) has a current E10 of R$-1.76. The current E10 is R$-1.76. Denali Therapeutics' overall GF Score™ is 6/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Denali Therapeutics (BSP:D2NL34), the current E10 is R$-1.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Denali Therapeutics Business Description

Other Exchanges DNLI:USA4DN:Germany
Address 161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
6GF Score

Get the complete analysis for BSP:D2NL34

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$27.06
Price